ArticleResearch and practice in thrombosis and haemostasis2025
Von Willebrand disease diagnosis: from complexity to simplicity.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Von Willebrand disease (VWD) is a complex disorder in terms of both its pathophysiology and treatment. The broad recognition and treatment of patients with VWD is often hindered by the complicated diagnostic process. Therefore, a more streamlined approach is needed, particularly in settings with limited expertise or resources. One practical initial strategy is to prioritize measuring von Willebrand factor (VWF) activity using a robust assay, alongside VWF antigen and factor (F)VIII levels, and administering a test dose of desmopressin. Once a diagnosis has been established, 3 variables should be considered for patients requiring replacement therapy: the patient's endogenous VWF activity and FVIII levels, and the quality of the infused multimers, as reflected by the VWF activity/antigen ratio of the concentrate. This simplified framework can facilitate the global diagnosis and management of VWD patients. However, we acknowledge the limitations, particularly with regard to accurately subtyping patients with type 2 VWD, since precise classification is essential for optimal care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.